TY - JOUR
T1 - The EURO-FORTA (Fit fOR The Aged) List Version 2
T2 - Consensus Validation of a Clinical Tool for Improved Pharmacotherapy in Older Adults
AU - Pazan, Farhad
AU - Weiss, Christel
AU - Wehling, Martin
AU - FORTA Expert Panel Members
AU - Wieczorowska-Tobis, Katarzyna
AU - Kostka, Tomasz
AU - Klich-Rączka, Alicja
AU - Bień, Barbara
AU - Broncel, Marlena
AU - Mierzejewski, Pawel
AU - Neumann-Podczaska, Agnieszka
AU - Onder, Graziano
AU - AntonelliIncalzi, Raffaele
AU - Cherubini, Antonio
AU - Ruggiero, Carmelinda
AU - Mugelli, Alessandro
AU - Johnell, Kristina
AU - Eriksson, Tommy
AU - Aalto, Ulla
AU - Gudmundsson, Adalsteinn
AU - Mañas, Leocadio Rodríguez
AU - Jentoft, Alfonso Jose Cruz
AU - Rexach, José Antonio Serra
AU - Agustí, Antònia
AU - Marum, Robvan
AU - van Poelgeest, Eveline P.
AU - van den Bemt, Patricia M. L. A.
AU - van der Cammen, Tischa J. M.
AU - Crome, Peter
AU - O’Mahony, Denis
AU - Byrne, Stephen
AU - Soiza, Roy L.
AU - Bauer, J. rgen M.
AU - Berthold, Heiner K.
AU - Denkinger, Michael
AU - von Arnim, Christine
AU - Dovjak, Peter
AU - Frohnhofen, Helmut
AU - Gosch, Markus
AU - Gutzmann, Hans
AU - Heuser-Collier, Isabella
AU - Honecker, Friedemann
AU - Hüll, Michael
AU - Iglseder, Bernhard
AU - Jaehde, Ulrich
AU - Kressig, Reto W.
AU - Kwetkat, Anja
AU - Schindler, Christoph
AU - Schulz, Ralf-Joachim
AU - Zeyfang, Andrej
AU - Pautex, Sophie
N1 - Funding Information: Collaborators’ names: Katarzyna Wieczorowska-Tobis, Tomasz Kostka, Alicja Klich-Rączka, Barbara Bień, Marlena Broncel, Pawel Mierzejewski, Agnieszka Neumann-Podczaska, Graziano Onder, Raffaele Antonelli Incalzi, Antonio Cherubini, Carmelinda Ruggiero, Alessandro Mugelli, Kristina Johnell, Tommy Eriksson, Ulla Aalto, Adalsteinn Gudmundsson, Leocadio Rodríguez Mañas, Alfonso Jose Cruz Jentoft, José Antonio Serra Rexach, Antònia Agustí, Rob van Marum, Eveline P. van Poelgeest, Patricia M. L. A. van den Bemt, Tischa J. M. van der Cammen, Peter Crome, Denis O’Mahony, Stephen Byrne, Roy L. Soiza, Jürgen M. Bauer, Heiner K. Berthold, Michael Denkinger, Christine von Arnim, Peter Dovjak, Helmut Frohnhofen, Markus Gosch, Hans Gutzmann, Isabella Heuser-Collier, Friedemann Honecker, Michael Hüll, Bernhard Iglseder, Ulrich Jaehde, Reto W. Kressig, Anja Kwetkat, Christoph Schindler, Ralf-Joachim Schulz, Andrej Zeyfang, Sophie Pautex, Ulrich Wedding, Cedric Annweiler, Dominique Somme, Mounir Rhalimi. The affiliations of the collaborators are listed in ESM 1–8. Publisher Copyright: © 2023, The Author(s).
PY - 2023/5
Y1 - 2023/5
N2 - Background: The aging of our societies leads to a higher prevalence of multimorbidity and therefore polypharmacy, which often results in inappropriate drug treatment. To address this issue, numerous listing approaches, such as the Fit fOR The Aged (FORTA) list have been developed. FORTA’s positive impact on the quality of medications and relevant clinical outcomes has been shown. Based on new emerging evidence and experiences with the existing FORTA lists, we aimed to update the FORTA lists in several European countries/regions. Methods: Two-step Delphi consensus procedures were conducted in Poland, UK/Ireland, Italy, Spain, the Nordic countries, The Netherlands and France. The existing European FORTA lists served as survey proposals. Results: Thirty-two experts agreed to take part in this study (return rate: 96.9%). The country/region-specific overall consensus for all items and participants after the first round was > 90%. FORTA lists from six participating countries, plus the FORTA list for the German-speaking countries, were collated into the new EURO-FORTA List, which now contains 267 items aligned to 27 indications. Three items were added to the EURO-FORTA List, and no drugs were deleted. Eight FORTA items were relabeled, and 96.9% of the labels remained unchanged. Conclusion: In this study, seven new country/region specific FORTA lists, as well as a new overarching EURO-FORTA List, were developed. An overall increase in the mean consensus coefficient and increases for all disease-specific mean consensus coefficients show a wider consensus among participants. The new lists have the potential to improve drug therapy in older people internationally.
AB - Background: The aging of our societies leads to a higher prevalence of multimorbidity and therefore polypharmacy, which often results in inappropriate drug treatment. To address this issue, numerous listing approaches, such as the Fit fOR The Aged (FORTA) list have been developed. FORTA’s positive impact on the quality of medications and relevant clinical outcomes has been shown. Based on new emerging evidence and experiences with the existing FORTA lists, we aimed to update the FORTA lists in several European countries/regions. Methods: Two-step Delphi consensus procedures were conducted in Poland, UK/Ireland, Italy, Spain, the Nordic countries, The Netherlands and France. The existing European FORTA lists served as survey proposals. Results: Thirty-two experts agreed to take part in this study (return rate: 96.9%). The country/region-specific overall consensus for all items and participants after the first round was > 90%. FORTA lists from six participating countries, plus the FORTA list for the German-speaking countries, were collated into the new EURO-FORTA List, which now contains 267 items aligned to 27 indications. Three items were added to the EURO-FORTA List, and no drugs were deleted. Eight FORTA items were relabeled, and 96.9% of the labels remained unchanged. Conclusion: In this study, seven new country/region specific FORTA lists, as well as a new overarching EURO-FORTA List, were developed. An overall increase in the mean consensus coefficient and increases for all disease-specific mean consensus coefficients show a wider consensus among participants. The new lists have the potential to improve drug therapy in older people internationally.
UR - http://www.scopus.com/inward/record.url?scp=85156202125&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s40266-023-01024-6
DO - https://doi.org/10.1007/s40266-023-01024-6
M3 - Article
C2 - 37129833
SN - 1170-229X
VL - 40
SP - 417
EP - 426
JO - Drugs & aging
JF - Drugs & aging
IS - 5
ER -